Tag: biotech

Forbion Expands Global Investment Leadership with Senior Promotions and Appointment of Operating Partner

Forbion announces the promotions of Jon Edwards, PhD, to General Partner, Regina Salvat, PhD, to Partner, and John McDonald, MBA, as Operating Partner.

Zifo Transforms EHS Policy Management with New AI-Enabled Services Accelerator

AI-powered EHS Compliance services accelerator is purpose-designed for pharma, biotech, and medical device companiesCAMBRIDGE, Mass. and CAMBRIDGE, England, June 5, 2026 /PRNewswire/ -- Zifo,...

Zifo Transforms EHS Policy Management with New AI-Enabled Services Accelerator

AI-powered EHS Compliance services accelerator is purpose-designed for pharma, biotech, and medical device companiesCAMBRIDGE, Mass. and CAMBRIDGE, England, June 5, 2026 /PRNewswire/ -- Zifo,...

Eratrectinib, the next-generation TRK inhibitor independently developed by Vcare PharmaTech, has received marketing approval

NANJING, China, June 5, 2026 /PRNewswire/ -- NTRK gene fusions have been identified as oncogenic drivers in adult and pediatric patients with pan-solid tumors....

MISOORA Unveils Revolutionary K-Beauty Skincare Range Emphasizing Longevity Over Anti-Aging

A five-step biotech regimen, anchored by NAD+ and Retinaldehyde, opens its founding waitlist ahead of a June 22 US debut.

A five-step biotech regimen, anchored by NAD+ and Retinaldehyde, opens its founding waitlist ahead of a June 22 US debut.

Greenland Mines Completes Site Visit to Sarfartoq Nd-Pr Rare Earth Magnet Project in Greenland; Prepares 2026 Field Program

CHARLOTTE, N.C., June 4, 2026 /PRNewswire/ -- Greenland Mines Ltd ("Greenland Mines" or the "Company") (Nasdaq: GRML) today announced that its Greenland operations team has...

Biofertilizer Market worth $6.94 billion by 2031- Exclusive Report by MarketsandMarkets™

DELRAY BEACH, Fla., June 4, 2026 /PRNewswire/ -- According to MarketsandMarkets™, the biofertilizer market is projected to grow from USD 4.08 billion in 2026 and to...

Biofertilizer Market worth $6.94 billion by 2031- Exclusive Report by MarketsandMarkets™

DELRAY BEACH, Fla., June 4, 2026 /PRNewswire/ -- According to MarketsandMarkets™, the biofertilizer market is projected to grow from USD 4.08 billion in 2026 and to...

【COMPUTEX 2026】Compal Integrates Quantum Technology and AI – Partnering with Top Universities and Pharmaceutical Firms to Build a Biotech AI Platform

TAIPEI, June 4, 2026 /PRNewswire/ -- Compal Electronics (Compal; TWSE: 2324) showcases its landmark achievements in Quantum Technology and Advanced Artificial Intelligence (AI) at COMPUTEX...

/C O R R E C T I O N — Oberland Biotech GmbH/

In the news release, Oberland Biotech GmbH Secures CHF 2.5 Million Seed Funding Round to Accelerate Global Expansion in Biotechnology and Food Innovation, issued...

Annual General Meeting on June 24, 2026 Procedures for obtaining preparatory documents for the General Meeting

Assemblée Générale Mixte du 24 juin 2026 Modalités de mise à disposition des documents préparatoires à l’Assemblée

ProBio and GCP ClinPlus Partner to Accelerate Clinical Trials in China

ProBio and GCP ClinPlus today announced a strategic collaboration designed to accelerate Investigator-Initiated Trials (IITs) in China and provide integrated, end-to-end clinical and development...

JJP Biologics Announces Positive Interim Phase 1b Data for Nebaprubart (JJP-1212), an Anti-CD89 Antagonist, in Linear IgA Disease (LAD)

Warsaw, Poland – June 03, 2026 – JJP Biologics, ("JJPBio" or the "Company") a clinical-stage, immune-focused biotech that engineers precision antibodies to correct derailed immune pathways that drive autoimmune diseases and cancer, today announces positive interim data from its ongoing Phase 1b trial evaluating nebaprubart, also known as JJP-1212, its investigational potential first-in-class anti-CD89 antagonist, in patients diagnosed with Linear IgA Disease (LAD), a rare autoantibody-mediated skin disease.

Johnson & Johnson late-breaking results show nipocalimab significantly reduced systemic lupus erythematosus (SLE) disease activity in a Phase 2 study

Nipocalimab – the first and only neonatal Fc receptor (FcRn) blocker to be studied in systemic lupus erythematosus – is designed to target and...

Huasun Ranked 12th on TIME’s World’s Top GreenTech Companies of 2026, Leaping 22 Places on the Strength of HJT Conviction

Scenic Biotech Joins Michael J. Fox Foundation’s LITE Program to Explore New Disease-Modifying Approach for Parkinson’s Disease

Zoetis Inc. Sued for Securities Law Violations – Contact the DJS Law Group to Discuss Your Rights – ZTS

Forbion Expands Global Investment Leadership with Senior Promotions and Appointment of Operating Partner

Zifo Transforms EHS Policy Management with New AI-Enabled Services Accelerator

Zifo Transforms EHS Policy Management with New AI-Enabled Services Accelerator

Eratrectinib, the next-generation TRK inhibitor independently developed by Vcare PharmaTech, has received marketing approval

MISOORA Unveils Revolutionary K-Beauty Skincare Range Emphasizing Longevity Over Anti-Aging

Greenland Mines Completes Site Visit to Sarfartoq Nd-Pr Rare Earth Magnet Project in Greenland; Prepares 2026 Field Program

Biofertilizer Market worth $6.94 billion by 2031- Exclusive Report by MarketsandMarkets™

Biofertilizer Market worth $6.94 billion by 2031- Exclusive Report by MarketsandMarkets™

【COMPUTEX 2026】Compal Integrates Quantum Technology and AI – Partnering with Top Universities and Pharmaceutical Firms to Build a Biotech AI Platform

/C O R R E C T I O N — Oberland Biotech GmbH/

Annual General Meeting on June 24, 2026 Procedures for obtaining preparatory documents for the General Meeting

ProBio and GCP ClinPlus Partner to Accelerate Clinical Trials in China

JJP Biologics Announces Positive Interim Phase 1b Data for Nebaprubart (JJP-1212), an Anti-CD89 Antagonist, in Linear IgA Disease (LAD)

Johnson & Johnson late-breaking results show nipocalimab significantly reduced systemic lupus erythematosus (SLE) disease activity in a Phase 2 study

Explore

Press Releases

News & Opinion

Living

Others

Follow us